- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01147029
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
A Cancer Research UK Phase I Trial of 4-(N-(S-Glutathionylacetyl) Amino) Phenylarsenoxide (GSAO) Given as Daily Intravenous Infusions on Days 1-5 and 8-12 of a 21-Day Cycle, to Patients With Advanced Solid Tumors
RATIONALE: GSAO may stop the growth of solid tumors by blocking blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of GSAO in treating patients with advanced solid tumors that have not responded to therapy.
연구 개요
상태
상세 설명
OBJECTIVES:
Primary
- To determine the maximum-tolerated dose and recommended phase II dose of angiogenesis inhibitor GSAO in patients with advanced, refractory solid tumors.
- To assess the safety and toxicity profile and dose-limiting toxicity of this drug in these patients.
Secondary
- To determine the pharmacokinetics of this drug in these patients.
- To determine the pharmacodynamics of this drug in these patients.
- To determine possible anti-tumor activity in patients treatment with this drug.
Tertiary
- To further determine the pharmacodynamics of this drug in these patients.
OUTLINE: This is a multicenter, dose-escalation study.
Patients receive angiogenesis inhibitor GSAO IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients showing clinical benefit (i.e., stable disease, partial response, or complete response) may receive 6 additional courses of treatment. Patients receive angiogenesis inhibitor GSAO IV over 1 hour on day -7 to obtain pharmacokinetics information of a single IV dose of the drug.
Patients also undergo dynamic contrast-enhanced magnetic-resonance imaging (DCE-MRI) prior to, during, and after study to determine blood flow parameters.
Blood samples are collected periodically for pharmacokinetic, pharmacodynamic, and biomarker studies.
After completion of study treatment, patients are followed up for 28 days and then once a month thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
England
-
Manchester, England, 영국, M20 4BX
- Christie Hospital
-
Oxford, England, 영국, OX3 7LJ
- Churchill Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically confirmed advanced solid tumor
- Refractory to conventional treatment or for which no conventional therapy exists
- Disease assessable by DCE-MRI and should be of a size that can be adequately assessed by these techniques
- No known primary brain tumors or brain metastases
PATIENT CHARACTERISTICS:
- WHO performance status 0-1
- Life expectancy ≥ 12 weeks
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 100 x 10^9/L
- Neutrophil count ≥ 1.5 x 10^9/L
- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT and AST ≤ 2.5 times ULN
- Creatinine clearance ≥ 50 mL/min (uncorrected value)
- Serum potassium and magnesium normal
- No proteinuria > grade 1 either on 24-hour urine or on 2 consecutive dipsticks taken no less than 1 week apart
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception 4 weeks prior to, during, and for 6 months after completion of study therapy
- Not at high medical risk due to non-malignant systemic disease, including active uncontrolled infection
- No serologically positive hepatitis B, hepatitis C, or HIV
- No concurrent congestive heart failure or prior NYHA class III-IV cardiac disease
None of the following medical conditions:
- Angina (stable or severe, even if well controlled on medication)
- Myocardial infarction in the past 2 months by ECG
- Congestive cardiac failure
- Arrhythmias, including any condition associated with QTc prolongation (e.g., Lange-Neilson syndrome or Romano Ward syndrome)
- Evidence of ischemia
- QTc > 480 msec
- Other clinically significant abnormalities
- No uncontrolled hypertension (defined as BP consistently greater than 160/100 mm Hg irrespective of medication)
- No other condition that, in the opinion of the investigator, would not make the patient a good candidate for this clinical trial
- No pacemakers
- No metal fragments in the eyes or shrapnel or bullet injuries
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from all prior treatments (except for alopecia or certain grade 1 toxicities which, in the opinion of the investigator and Cancer Research UK, should not exclude the patient)
- At least 4 weeks since prior radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)
- At least 1 week since prior and no concurrent shellfish
- At least 6 weeks since prior major surgery (including thoracic and/or abdominal surgery) and recovered
- Concurrent luteinizing-hormone releasing-hormone (LHRH) analogues allowed for patients with castration-refractory prostate cancer provided the prostate-specific antigen level is rising
- No prior heart or brain surgery
- No concurrent drug known to prolong the QTc interval
- No concurrent warfarin (1 mg for maintenance of a Hickman line is acceptable) or heparin (flushing of arterial lines, if necessary, is acceptable)
- No concurrent naproxen (other NSAIDs are acceptable)
No concurrent prophylactic use of antiemetics during the first treatment
- Domperidone and lorazepam must not be used as antiemetics
No other concurrent anticancer therapy or investigational drugs
- Concurrent bisphosphonates allowed
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
---|
용량 제한 독성
|
Causality of each adverse event and grading severity according to NCI CTCAE Version 3.0
|
2차 결과 측정
결과 측정 |
---|
Relationship between pharmacokinetics and toxicity and/or markers of efficacy
|
Changes in microvascular function using DCE-MRI
|
Plasma and tumor levels of angiogenic factors and apoptosis markers
|
Response (stable disease, partial response, or complete response) as determined by RECIST criteria
|
Circulating endothelial cells and circulating endothelial progenitor cells as a marker of inhibition of angiogenesis
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Gordon Jayson, MD, The Christie NHS Foundation Trust
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- CDR0000675271
- CRUK-PH1-109
- EUDRACT-2006-002326-34
- CTA-21106-0222-001
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
약리학적 연구에 대한 임상 시험
-
Helse-Bergen HFUniversity Hospital of North Norway; Helse Forde완전한발달성 고관절 이형성증
-
Radicle Science모집하지 않고 적극적으로
-
Fonds de la Recherche en Santé du QuébecUniversité de Montréal완전한
-
Hospital Clinic of BarcelonaUniversitat Politècnica de Catalunya; Institut Catala de Salut; Department of Health, Generalitat... 그리고 다른 협력자들알려지지 않은
-
Radicle Science모집하지 않고 적극적으로
-
Rajiv Gandhi Cancer Institute & Research Center...완전한